Corvus Pharmaceuticals, Inc. (CRVS) - Form 8-K Summary
Business Context and Reporting Period
Corvus Pharmaceuticals, Inc., a Delaware corporation, filed this Current Report on Form 8-K on March 12, 2026. The filing serves to announce the company's financial results for the fourth quarter and full year ended December 31, 2025, along with a business update. The company's common stock trades on the Nasdaq Global Market under the symbol CRVS.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the source text provided.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms that a press release detailing the fourth quarter and full-year 2025 results was issued on March 12, 2026.
Guidance, Outlook, and Risks
The filing indicates that management provided a business update alongside the financial results. However, the text of this 8-K does not include specific guidance, outlook figures, risk factors, contingencies, or unusual items. The information in Item 2.02 and Exhibit 99.1 is explicitly stated as not being "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 12, 2026) for specific Q4 and full-year 2025 financial figures.
- Verify the company's cash position and runway based on the full-year 2025 results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the business update.
- Confirm if the company has provided updated financial guidance for 2026 in the press release.